Nykode Therapeutics ASA
Clinical-stage biopharma developing novel immunotherapies for oncology and diseases.
NYKD | OL
Overview
Corporate Details
- ISIN(s):
- NO0010714785
- LEI:
- 254900UKQHWYZJD22017
- Country:
- Norway
- Address:
- Gaustadalleen 21, 0349 Oslo
- Website:
- https://nykode.com/
- Sector:
- Manufacturing
Description
Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-24 16:40 |
Nykode Therapeutics - Mandatory notification of acquisition of shares by primar…
|
English | 191.8 KB | ||
| 2025-11-24 16:40 |
Nykode Therapeutics - Mandatory notification of acquisition of shares by primar…
|
English | 706 bytes | ||
| 2025-11-24 07:00 |
Nykode Therapeutics - Quarterly Report Q3 2025 - Attachment: 251124 Nykode Quar…
|
English | 11.3 MB | ||
| 2025-11-24 07:00 |
Nykode Therapeutics - Quarterly Report Q3 2025
|
English | 3.0 KB | ||
| 2025-11-13 08:00 |
Nykode Therapeutics – Invitation to Q3 2025 Financial Results Presentation - At…
|
Norwegian | 126.0 KB | ||
| 2025-11-13 08:00 |
Nykode Therapeutics – Invitation to Q3 2025 Financial Results Presentation
|
English | 3.3 KB | ||
| 2025-11-05 07:00 |
Nykode Therapeutics to Present Data on the Strength of the Neoantigen Selection…
|
English | 221.0 KB | ||
| 2025-11-05 07:00 |
Nykode Therapeutics to Present Data on the Strength of the Neoantigen Selection…
|
English | 6.8 KB | ||
| 2025-11-04 07:00 |
Nykode Therapeutics Strengthens Intellectual Property Portfolio with New U.S. P…
|
English | 140.5 KB | ||
| 2025-11-04 07:00 |
Nykode Therapeutics Strengthens Intellectual Property Portfolio with New U.S. P…
|
English | 5.3 KB | ||
| 2025-10-14 08:17 |
Disclosure of Large Shareholding - Nykode Therapeutics ASA - Attachment: CGC_21…
|
English | 165.9 KB | ||
| 2025-10-14 08:17 |
Disclosure of Large Shareholding - Nykode Therapeutics ASA - Attachment: SCWF_2…
|
English | 162.4 KB | ||
| 2025-10-14 08:17 |
Disclosure of Large Shareholding - Nykode Therapeutics ASA
|
English | 1.0 KB | ||
| 2025-10-10 17:44 |
Nykode Therapeutics – Grant of Share Options - Attachment: Attachment Options 2…
|
English | 181.6 KB | ||
| 2025-10-10 17:44 |
Nykode Therapeutics – Grant of Share Options
|
English | 775 bytes |
Automate Your Workflow. Get a real-time feed of all Nykode Therapeutics ASA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nykode Therapeutics ASA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nykode Therapeutics ASA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
